Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Cancer biology

T cells target solid tumours

A cancer therapy that uses genetically modified versions of patients' immune cells to treat blood cancers has been adapted to attack solid human tumours implanted into mice.

Engineered T cells are designed to home in on specific proteins on the surface of cancer cells in the blood — but adenocarcinomas, a common type of solid tumour, rarely carry such markers. Avery Posey and Carl June of the University of Pennsylvania in Philadelphia and their colleagues developed a way to modify human T cells so that they recognize abnormal forms of a sugar molecule linked to a cell-surface protein that is abundant in many cancers. The authors found that in a mouse model of human pancreatic adenocarcinoma, all animals treated with these T cells survived until the end of the experiment, compared with only 40% of untreated controls.

Protein-linked sugars are a promising target for cancer immunotherapy, the team says.

Immunity 44, 1444–1454 (2016)

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

T cells target solid tumours. Nature 534, 593 (2016).

Download citation


Quick links